Abstract: An encoder operable to filter audio signals into a plurality of frequency band components, generate quantized digital components for each band, identify a potential for pre-echo events within the generated quantized digital components, generate an approximate signal by decoding the quantized digital components using inverse pulse code modulation, generate an error signal by comparing the approximate signal with the sampled audio signal, and process the error signal and quantized digital components. The encoder operable to process the error signal by processing delayed audio signals and Q band values, determining the potential for pre-echo events from the Q band values, and determining scale factors and MDCT block sizes for the potential for pre-echo events.

Abstract: An interactive system may include (1) a facial coupling subsystem configured to conduct a biopotential signal generated by a user's body, (2) a receiving subsystem electrically connected to the facial coupling subsystem and configured to receive, from the user's body via a compliant electrode of the facial coupling subsystem, the biopotential signal, and (3) a detection subsystem electrically connected to the receiving subsystem and configured to (a) determine a characteristic of the biopotential signal and (b) use the characteristic of the biopotential signal to determine a gaze direction of an eye of the user and/or a facial gesture of the user. In some examples, the facial coupling subsystem may include a plurality of compliant electrodes that each are configured to comply in a direction normal to a surface of the user's face. Various other apparatus, systems, and methods are also disclosed.

Abstract: An interactive system (e.g., a head-mounted-display device) may include (1) a facial coupling subsystem having electrodes configured to conduct at least one biopotential signal (e.g., an EOG or EMG signal) generated by a user's body, (2) a receiving subsystem electrically connected to the facial coupling subsystem and configured to receive, from the user's body via at least one electrode of the facial coupling subsystem, the biopotential signal, and (3) a detection subsystem electrically connected to the receiving subsystem and configured to (a) determine at least one characteristic of the biopotential signal and (b) use the at least one characteristic of the biopotential signal to determine a gaze direction of an eye of the user and/or a facial gesture of the user. Various other apparatus, systems, and methods are also disclosed.

Abstract: A portable computer numerically controlled non-contact cutting apparatus is provided comprising a housing, and an arm having a base portion attached to the housing and movable along a longitudinal axis of the housing. The arm may comprise a head assembly adapted to receive a cutting device, the head assembly may be movable along a longitudinal axis of the arm, and the arm may be rotatable about the base portion relative to the longitudinal axis of the housing from a retracted position to an extended position. Further, the arm may be adapted to be releasably held in the extended position.

Abstract: The present disclosure concerns a compound, or a pharmaceutically acceptable salt thereof, having a formula: where at least one of R1-R4 is a heterocycle, at least one of R1-R4 is an aryl group coupled to the ring by a linker atom, functional group, or other moiety, or where none of R1-R4 is an amide, and any and all combinations thereof. Remaining R1-R4 substituents independently are aliphatic, substituted aliphatic, amine, substituted amine, aryl, substituted aryl, cyclic, substituted cyclic, halide, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, hydrogen or hydroxyl. A method for treating a subject also is provided comprising administering a disclosed compound or compounds, or a prodrug that is converted into the disclosed compound or compounds, or a composition comprising the compound, compounds, or prodrugs thereof, to a subject. A method for making disclosed compounds also is provided.

Abstract: The present disclosure concerns a compound, or a pharmaceutically acceptable salt thereof, having a formula: where at least one of R1-R4 is a heterocycle, at least one of R1-R4 is an aryl group coupled to the ring by a linker atom, functional group, or other moiety, or where none of R1-R4 is an amide, and any and all combinations thereof. Remaining R1-R4 substituents independently are aliphatic, substituted aliphatic, amine, substituted amine, aryl, substituted aryl, cyclic, substituted cyclic, halide, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, hydrogen or hydroxyl. A method for treating a subject also is provided comprising administering a disclosed compound or compounds, or a prodrug that is converted into the disclosed compound or compounds, or a composition comprising the compound, compounds, or prodrugs thereof, to a subject. A method for making disclosed compounds also is provided.

Abstract: A method for making epothilones and epothilone analogs is described, as are novel compounds made by the method. One embodiment of the method was used to synthesize epothilone B by a convergent approach that entailed Wittig coupling of an ylide derived from phosphonium bromide with an aldehyde. The former was prepared from propargyl alcohol by a nine-step pathway which installed both trisubstituted double bonds with clean Z configuration. Macrolactonization of a resulting seco acid provided the following intermediate diene epothilone analog.

Abstract: A method for making epothilones and epothilone analogs is described, as are novel compounds made by the method. One embodiment of the method was used to synthesize epothilone B by a convergent approach that entailed Wittig coupling of an ylide derived from phosphonium bromide with an aldehyde. The former was prepared from propargyl alcohol by a nine-step pathway which installed both trisubstituted double bonds with clean Z configuration. Macrolactonization of a resulting seco acid provided the following intermediate diene epothilone analog. Selective saturation of the 9,10-olefin and subsequent epoxidation provided epothilone B.

Abstract: A method for making epothilones and epothilone analogs is described, as are novel compounds made by the method. Exemplary novel compounds include those according to the formula: With respect the formula, G is selected from the group consisting of R2 substituents independently are selected from the group consisting of H and lower alkyl groups; Z is selected from the group consisting of the halogens and —CN; M is selected from the group consisting of O and NR3; R3 is selected from the group consisting of H, lower alkyl, R4CO, R4OCO, and R4SO2; R4 is selected from the group consisting of H, lower alkyl, and aryl; T is selected from the group consisting of CH2, CO, HCOH and protected derivatives thereof; W is H or OR; and X and Y independently are selected from the group consisting of O, NH, S, CO, and C.

Abstract: A method for making epothilones and epothilone analogs is described, as are novel compounds made by the method.

Abstract: A method for making epothilones and epothilone analogs is described, as are novel compounds made by the method. One embodiment of the method was used to synthesize epothilone B by a convergent approach that entailed Wittig coupling of an ylide derived from phosphonium bromide with an aldehyde. The former was prepared from propargyl alcohol by a nine-step pathway which installed both trisubstituted double bonds with clean Z configuration. Macrolactonization of a resulting seco acid provided the following intermediate diene epothilone analog. Selective saturation of the 9,10-olefin and subsequent epoxidation provided epothilone B.

Abstract: A method for making epothilones and epothilone analogs is described, as are novel compounds made by the method. One embodiment of the method was used to synthesize epothilone B by a convergent approach that entailed Wittig coupling of an ylide derived from phosphonium bromide with an aldehyde. The former was prepared from propargyl alcohol by a nine-step pathway which installed both trisubstituted double bonds with clean Z configuration. Macrolactonization of a resulting seco acid provided the following intermediate diene epothilone analog. Selective saturation of the 9,10-olefin and subsequent epoxidation provided epothilone B.

Abstract: An aqueous ink jet ink is disclosed which comprises an effective amount of an azomethine dye having at least one water solubilizing functional group covalently attached thereto. The water solubilizing functional group can either be directly attached to the azomethine dye and/or can be attached to the azomethine dye through an electrophilic coupling moiety. If an organic spacer group is used to separate the water solubilizing functional group from azomethine dye or the electrophilic coupling moiety, then straight and branched chained alkyl groups having from about 1 to 10 carbon atoms is preferred. Preferred azomethine dyes can be pyrazolone azomethines, pyrazolotriazole azomethines, and combinations thereof. Additionally, an aqueous ink jet ink is disclosed comprising an effective amount of a dye-based colorant and an essentially water soluble spiroindane additive for improving light fastness and stability of the dye-based colorant.

Abstract: A method for making epothilones and epothilone analogs is described, as are novel compounds made by the method. One embodiment of the method was used to synthesize epothilone B by a convergent approach that entailed Wittig coupling of an ylide derived from phosphonium bromide with an aldehyde. The former was prepared from propargyl alcohol by a nine-step pathway which installed both trisubstituted double bonds with clean Z configuration. Macrolactonization of a resulting seco acid provided the following intermediate diene epothilone analog. Selective saturation of the 9,10-olefin and subsequent epoxidation provided epothilone B.